Hims & Hers Health (NYSE:HIMS) Issues Quarterly Earnings Results, Meets Expectations

Hims & Hers Health (NYSE:HIMS) announced its earnings results on Monday. The company reported $0.09 EPS for the quarter, hitting the consensus estimate of $0.09, Zacks reports. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%. Hims & Hers Health updated its FY 2025 guidance to EPS and its Q4 2025 guidance to EPS.

Hims & Hers Health Stock Down 2.5%

Shares of Hims & Hers Health stock traded down $1.12 on Monday, hitting $44.34. 37,632,759 shares of the company traded hands, compared to its average volume of 32,339,678. The company has a 50-day moving average price of $51.39 and a 200 day moving average price of $50.61. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. Hims & Hers Health has a 12-month low of $19.15 and a 12-month high of $72.98. The company has a market cap of $10.02 billion, a PE ratio of 55.43, a PEG ratio of 3.15 and a beta of 2.20.

Insider Activity at Hims & Hers Health

In related news, insider Michael Chi sold 13,749 shares of Hims & Hers Health stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total value of $694,324.50. Following the completion of the sale, the insider owned 297,139 shares of the company’s stock, valued at approximately $15,005,519.50. The trade was a 4.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Patrick Harrison Carroll sold 60,000 shares of Hims & Hers Health stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the completion of the sale, the insider directly owned 169,940 shares of the company’s stock, valued at approximately $9,105,385.20. The trade was a 26.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 1,432,271 shares of company stock valued at $74,229,585. Insiders own 17.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently modified their holdings of the business. EverSource Wealth Advisors LLC lifted its stake in shares of Hims & Hers Health by 273.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock valued at $47,000 after purchasing an additional 687 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in Hims & Hers Health during the 1st quarter worth $30,000. Palisade Capital Management LP acquired a new position in Hims & Hers Health during the 2nd quarter worth $224,000. SkyView Investment Advisors LLC acquired a new position in Hims & Hers Health during the 2nd quarter worth $226,000. Finally, Meiji Yasuda Asset Management Co Ltd. acquired a new position in Hims & Hers Health during the 2nd quarter worth $234,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on HIMS shares. Wall Street Zen cut Hims & Hers Health from a “buy” rating to a “hold” rating in a report on Monday, July 28th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $68.00 price target on shares of Hims & Hers Health in a report on Friday, September 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. KeyCorp initiated coverage on Hims & Hers Health in a report on Tuesday, October 21st. They issued a “sector weight” rating on the stock. Finally, Zacks Research cut Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Two investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average price target of $38.92.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.